Gastroenterology

TNF-α antagonists superior to vedolizumab, ustekinumab for endoscopic healing in CD

Stephen Padilla, 2 days ago

The tumour necrosis factor-alpha (TNF-α) antagonist therapies adalimumab and infliximab are more effective than vedolizumab and ustekinumab in achieving endoscopic healing (EH) at 1 year among patients with moderate-to-severe Crohn’s disease (CD), a recent study has shown.

Gastric disease prevalence peaks during middle age, late adulthood

Tristan Manalac, 2 days ago

There appears to be a twin-peak prevalence profile (TPP) for diseases of the stomach, including Helicobacter pylori (Hp) infection, gastric cancer (GC), gastric intraepithelial neoplasia (GIN), and gastritis, according to a recent China study. The first peak typically occurs during middle-adulthood while the second peak happens in late life.

Artificial intelligence in colonoscopy promises better adenoma detection

Jairia Dela Cruz, 4 days ago

A real-time artificial intelligence (AI)-assisted colonoscopy device has the potential to improve the detection of polyps, including difficult-to-detect adenomas, even for experienced endoscopists, as shown in a study from Singapore.

Myocardial infarction after GI bleeding ups in-hospital mortality, resource use

5 days ago

A diagnosis of type 1 or type 2 myocardial infarction (MI) following hospitalization for gastrointestinal bleeding (GIB) often leads to higher in-hospital mortality and resource utilization, results of a recent US study have shown.

Tenofovir in mothers plus HBIG in infants best prevent vertical HBV transmission

5 days ago

For mothers with hepatitis B virus (HBV) infection who are positive for both hepatitis B surface and envelope antigens, administering a combination of hepatitis B vaccine and immunoglobulin (HBIG) in their infants plus tenofovir disoproxil fumarate (TDF) in the mothers themselves appears to be the best approach for preventing vertical disease transmission, according to a study.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).

CD-TREAT diet induces response/remission, improves QoL in patients with active CD

Elaine Soliven, 21 Jul 2022

CD-TREAT* diet, a food-based diet with a similar dietary profile to exclusive enteral nutrition (EEN), induces clinical response or remission and improves quality of life (QoL) in children and adults with active Crohn’s disease (CD), according to a study presented at ESPGHAN 2022.

Real-world studies demonstrate TAF efficacy and safety in chronic hep B

Roshini Claire Anthony, 20 Jul 2022

Treatment with tenofovir alafenamide (TAF) results in similar virological response compared with tenofovir disoproxil fumarate (TDF) in treatment-naïve patients with chronic hepatitis B (CHB), according to a real-world study from Korea presented at ILC 2022.

Resmetirom demos potential in NASH

Roshini Claire Anthony, 18 Jul 2022

Safety analysis of the phase III MAESTRO-NAFLD-1 trial presented at ILC 2022 demonstrated the potential of resmetirom as a treatment for patients with non-alcoholic steatohepatitis (NASH) who have liver fibrosis.

High-dose zinc intake tied to less feeding intolerance in VLBW infants

Elaine Soliven, 06 Jul 2022

High-dose zinc supplementation was significantly associated with decreased feeding intolerance in very low birth weight (VLBW) preterm infants, according to a study presented at ESPGHAN 2022.

Methotrexate proven safe, effective as first-line immunomodulator in paediatric CD

Stephen Padilla, 30 Jun 2022

Use of methotrexate (MTX) appears safe and effective as first-line immunomodulator for maintenance therapy in children with Crohn’s disease (CD), suggests a study presented at the 54th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN 2022).

$Prucalopride offers relief in children with refractory idiopathic constipation$

Prucalopride offers relief in children with refractory idiopathic constipation

Jairia Dela Cruz, 28 Jun 2022

Three out of five teens with refractory constipation achieve improvements in bowel movement with prucalopride, while having acceptable side effect profiles, as shown in a small study.

Infliximab, adalimumab biosimilars effective, safe in paediatric IBD

Tristan Manalac, 27 Jun 2022

The use of biosimilars of infliximab (IFX) and adalimumab (ADA) is both safe and effective in children with inflammatory bowel disease (IBD), inducing high rates of failure-free survival with a low incidence of adverse events, according to a study presented at the 2022 Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN 2022).